Composition comprising antigen presenting cell co-expressing MHC and tumor antigen and treatment of cancer using the same
By using a bicistronic gene construct to overexpress patient-specific MHC alleles and tumor antigens on antigen-presenting cells, the limitations of existing vaccines are overcome, achieving enhanced tumor antigen presentation and potent anticancer immune responses.
Patent Information
- Authority / Receiving Office
- KR · KR
- Patent Type
- Patents
- Current Assignee / Owner
- LG CHEM LTD
- Filing Date
- 2021-01-08
- Publication Date
- 2026-07-21
AI Technical Summary
Existing anticancer therapeutic cell vaccines are limited by the mechanistic constraints of MHC alleles and expression levels in antigen-presenting cells, restricting the range of epitope sequences and overall antigen presentation efficacy, particularly for diverse patient-specific neoantigens.
A bicistronic gene construct or mRNA transcript simultaneously expresses patient tumor-derived MHC alleles and tumor antigens, overexpressing them on the surface of antigen-presenting cells to maximize epitope-MHC immunostimulatory complexes, thereby triggering robust patient-specific anticancer T cell responses.
This approach enhances tumor antigen presentation efficacy, leading to the maximum proliferation and activation of patient-specific anticancer T cells, increasing the neoantigen-specific immune effect and improving cancer treatment outcomes.
Smart Images
Figure 112021002711345-PAT00001_ABST